Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C
BACKGROUND/AIMS: The purpose of this study is to elucidate the efficacy and safety of combined peginterferon and ribavirin therapy in Korean patients with chronic HCV infection.
METHODS: We retrospectively analyzed the clinical records of 84 patients. Thirty five patients with genotype 1 HCV infection were treated with peginterferon alpha-2a 180 microg/week and ribavirin 1,000-1,200 mg/day for 48 weeks, and 49 patients with genotype non-1 were treated with peginterferon alpha-2a 180 microg/week and ribavirin 800 mg/day for 24 weeks.
RESULTS: An early virologic response was seen in 87.0% of patients with genotype 1 HCV. An end of treatment response (ETR) was seen in 82.6% and 97.6% of patients with genotype 1 and genotype non-1, respectively. An overall sustained virologic response (SVR) was seen in 53 patients (82.8%) of the 64 patients: in 16 (69.6%) of 23 patients with genotype 1 and in 37 (90.2%) of 41 patients with genotype non-1. An end of treatment biochemical response was seen in 58 patients (90.6%) [genotype 1, 20 patients (87.0%); genotype non-1, 38 patients (92.7%)], and a sustained biochemical response was achieved in 49 patients (76.6%) [genotype 1, 14 patients (60.9%); genotype non-1, 35 patients (85.4%)]. Independent factors affecting an SVR were HCV genotype and the baseline HCV RNA level.
CONCLUSIONS: This study shows that a combination therapy of peginterferon and ribavirin is highly effective for chronic HCV infection, producing a high SVR and ETR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2008 |
|---|---|
| Erschienen: |
2008 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
The Korean journal of hepatology - 14(2008), 1 vom: 21. März, Seite 36-45 |
| Sprache: |
Koreanisch |
|---|
| Beteiligte Personen: |
Kim, Kyoung-Tae [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3WJQ0SDW1A |
|---|
| Anmerkungen: |
Date Completed 05.12.2008 Date Revised 01.12.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3350/kjhep.2008.14.1.36 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM178503878 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM178503878 | ||
| 003 | DE-627 | ||
| 005 | 20231223152218.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2008 xx |||||o 00| ||kor c | ||
| 024 | 7 | |a 10.3350/kjhep.2008.14.1.36 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0595.xml |
| 035 | |a (DE-627)NLM178503878 | ||
| 035 | |a (NLM)18367856 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a kor | ||
| 100 | 1 | |a Kim, Kyoung-Tae |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C |
| 264 | 1 | |c 2008 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.12.2008 | ||
| 500 | |a Date Revised 01.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND/AIMS: The purpose of this study is to elucidate the efficacy and safety of combined peginterferon and ribavirin therapy in Korean patients with chronic HCV infection | ||
| 520 | |a METHODS: We retrospectively analyzed the clinical records of 84 patients. Thirty five patients with genotype 1 HCV infection were treated with peginterferon alpha-2a 180 microg/week and ribavirin 1,000-1,200 mg/day for 48 weeks, and 49 patients with genotype non-1 were treated with peginterferon alpha-2a 180 microg/week and ribavirin 800 mg/day for 24 weeks | ||
| 520 | |a RESULTS: An early virologic response was seen in 87.0% of patients with genotype 1 HCV. An end of treatment response (ETR) was seen in 82.6% and 97.6% of patients with genotype 1 and genotype non-1, respectively. An overall sustained virologic response (SVR) was seen in 53 patients (82.8%) of the 64 patients: in 16 (69.6%) of 23 patients with genotype 1 and in 37 (90.2%) of 41 patients with genotype non-1. An end of treatment biochemical response was seen in 58 patients (90.6%) [genotype 1, 20 patients (87.0%); genotype non-1, 38 patients (92.7%)], and a sustained biochemical response was achieved in 49 patients (76.6%) [genotype 1, 14 patients (60.9%); genotype non-1, 35 patients (85.4%)]. Independent factors affecting an SVR were HCV genotype and the baseline HCV RNA level | ||
| 520 | |a CONCLUSIONS: This study shows that a combination therapy of peginterferon and ribavirin is highly effective for chronic HCV infection, producing a high SVR and ETR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Interferon alpha-2 |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a Ribavirin |2 NLM | |
| 650 | 7 | |a 49717AWG6K |2 NLM | |
| 650 | 7 | |a peginterferon alfa-2a |2 NLM | |
| 650 | 7 | |a Q46947FE7K |2 NLM | |
| 700 | 1 | |a Han, Sang-Young |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jong-Han |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Hyun-Ah |e verfasserin |4 aut | |
| 700 | 1 | |a Baek, Yang-Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Min-Ji |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sung-Wook |e verfasserin |4 aut | |
| 700 | 1 | |a Jang, Jin-Seok |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jong-Hun |e verfasserin |4 aut | |
| 700 | 1 | |a Roh, Myung-Hwan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Korean journal of hepatology |d 2004 |g 14(2008), 1 vom: 21. März, Seite 36-45 |w (DE-627)NLM147902967 |x 1738-222X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2008 |g number:1 |g day:21 |g month:03 |g pages:36-45 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3350/kjhep.2008.14.1.36 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2008 |e 1 |b 21 |c 03 |h 36-45 | ||